Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study

The exact dose of cytarabine still remain controversial for the management of patients with acute myeloid leukemia (AML) after complete remission (CR), but recent studies favor lower doses. This study aimed to investigate the toxic effects of single-intermediate dose (ID) cytarabine in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Li, Gao, Lingsu, Cheng, Qiansong, Guo, Feng, He, Liang, Yuan, Tingting, Zhu, Ming, Ma, Yuanfang, Pan, Min, Chu, Xiandeng, Ding, Meiqi, Yu, Guohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837979/
https://www.ncbi.nlm.nih.gov/pubmed/33546048
http://dx.doi.org/10.1097/MD.0000000000024273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837979/
https://www.ncbi.nlm.nih.gov/pubmed/33546048
http://dx.doi.org/10.1097/MD.0000000000024273

Ejemplares similares